Skip to main content
Equibles

Dave Reisinger

Analyst

Leerink Partners

Equibles does not estimate personal net worth.

About Dave Reisinger

Dave Reisinger is recorded as Analyst at Leerink Partners. Dave Reisinger has spoken on 5 earnings calls across 5 companies, most recently for Halozyme Therapeutics, Inc. on August 6, 2026. Those appearances were for Halozyme Therapeutics, Inc. (HALO), Amgen Inc (AMGN), Immunovant, Inc. (IMVT), Roivant Sciences Ltd. (ROIV) and Pfizer Inc (PFE). The companies whose calls Dave Reisinger spoke on are classified in the Healthcare sector.

Dave Reisinger on recent calls

“First, could you provide an update on the Merck litigation prospects? That's the first question. Second, how you see Alteogen as a competitor today? And then third, your view on the acquisition landscape.”
Analyst — Leerink Partners, Halozyme to Report Second Quarter 2026 Financial and Operating Results ·
“Thanks very much, and thanks for all of the details today and all the commentary on the pipeline. So, my question is for Jay, please. Regarding Meritide's construct, so it's GLP-1 peptides conjugated to a GIP antagonist antibody, of course.”
Analyst — Leerink Partners, Amgen Inc Q2 FY2026 Earnings Call ·
“And let me add my congrats as well, Matt and team. So obviously the data was phenomenal. I had a couple of questions. First, with respect to the headline CSAMI numbers, you know, they were similar between the two arms.”
Analyst — Leerink Partners, Roivant 3Q 2025 Earnings Call ·
“And let me add my congrats as well, Matt and team. So obviously the data was phenomenal. I had a couple of questions. First, with respect to the headline CSAMI numbers, you know, they were similar between the two arms.”
Analyst — Leerink Partners, Roivant 3Q 2025 Earnings Call ·
“Chris, could you talk a little bit more about MET-233i, which I believe is now numbered 3945, specifically the bias of amylin relative to calcitonin, the implications for the efficacy and tolerability profile, and the data we should expect at ADA?”
Analyst — Leerink Partners, Pfizer Inc Q4 FY2025 Earnings Call ·

Affiliation history

  • Leerink Partners

    Analyst

    Transcript header (unverified)

    Current

Company network

Recent activity